(Q38719567)

English

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus

scientific article published on 24 January 2017

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

influenza A virus

object named as

influenza A virus

1 reference

based on heuristic

inferred from title

author name string

Fatemeh Fotouhi

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Mina Shaffifar

2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Behrokh Farahmand

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sadegh Shirian

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Mohsen Saeidi

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Alijan Tabarraei

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Ali Gorji

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Amir Ghaemi

8

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

24 January 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Archives of Virology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

162

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1251-1260

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

NKT cell subsets as key participants in liver physiology and pathology

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Harnessing invariant NKT cells in vaccination strategies

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Activation of NKT cells protects mice from tuberculosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

M2e-Based Universal Influenza A Vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Global burden of influenza as a cause of cardiopulmonary morbidity and mortality

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Innate immunity to influenza virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

DNA vaccines: ready for prime time?

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

NKT cell networks in the regulation of tumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Comparing the effect of Toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Universal influenza vaccines: Shifting to better vaccines.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Protection in mice immunized with a heterologous prime-boost regime using DNA and recombinant pseudorabies expressing TgSAG1 against Toxoplasma gondii challenge

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Activation or anergy: NKT cells are stunned by alpha-galactosylceramide

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Antitumor effect of therapeutic HPV DNA vaccines with chitosan-based nanodelivery systems.

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus

1 reference

https://api.crossref.org/works/10.1007%2FS00705-017-3230-7

21 January 2018

Identifiers

10.1007/S00705-017-3230-7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38719567&oldid=2202008554"